Equities research analysts expect Enfusion Inc (NYSE:ENFN) to report $0.04 earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have made estimates for Enfusion’s earnings. The firm is scheduled to issue its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Enfusion will report full-year earnings of $0.13 per share for the current fiscal year, with EPS estimates ranging from $0.12 to $0.13. For the next financial year, analysts forecast that the business will report earnings of $0.28 per share, with EPS estimates ranging from $0.28 to $0.29. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Enfusion.
ENFN has been the topic of a number of analyst reports. Credit Suisse Group lowered their target price on shares of Enfusion from $26.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, December 3rd. The Goldman Sachs Group began coverage on shares of Enfusion in a research note on Monday, November 15th. They set a “neutral” rating and a $26.00 price objective on the stock. Stifel Nicolaus began coverage on shares of Enfusion in a research note on Monday, November 15th. They set a “buy” rating and a $27.00 price objective on the stock. Morgan Stanley decreased their price objective on shares of Enfusion from $24.00 to $22.00 and set an “equal weight” rating on the stock in a research note on Friday, December 3rd. Finally, William Blair began coverage on shares of Enfusion in a research note on Monday, November 15th. They set an “outperform” rating on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Enfusion presently has a consensus rating of “Buy” and an average target price of $25.20.
In other news, major shareholder Hillhouse Investment Managemen sold 647,862 shares of the stock in a transaction that occurred on Monday, October 25th. The shares were sold at an average price of $15.89, for a total transaction of $10,294,527.18. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Roy Luo acquired 1,261,594 shares of the business’s stock in a transaction that occurred on Monday, October 25th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $21,447,098.00. The disclosure for this purchase can be found here.
Enfusion Inc is a provider of cloud-based investment management software and services. Through its software, analytics and middle/back-office managed services, it creates enterprise-wide cultures of real-time, data-driven intelligence, boosting agility and powering growth. Enfusion Inc is based in NEW YORK.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.